Dan Loeb’s Third Point Capital has built a stake in Tylenol and Neutrogena maker Kenvue (KVUE), people familiar with the matter told Financial Times’ Oliver Barnes and Amelia Pollard. Third Point’s position in Kenvue makes it the third activist hedge fund to target the consumer health group in recent months, which may add pressure on the company’s management, the report said. Kenvue, which was spun out of Johnson & Johnson (JNJ) in 2023, has “increasingly been viewed as a takeover target,” the report added.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KVUE: